The effects of anti-lung cancer in nude mice by a fully human single-chain antibody against associated antigen Ts7TMR between A549 cells and Trichinella spiralis.

IF 4.5 3区生物学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Artificial Cells, Nanomedicine, and Biotechnology Pub Date : 2024-12-01 Epub Date: 2024-05-16 DOI:10.1080/21691401.2024.2347377

Taotao Yue, Jinpeng Wang, Fang Liu, Pengtao Gong, Jianhua Li, Xichen Zhang, Nan Zhang

{"title":"The effects of anti-lung cancer in nude mice by a fully human single-chain antibody against associated antigen Ts7TMR between A549 cells and Trichinella spiralis.","authors":"Taotao Yue, Jinpeng Wang, Fang Liu, Pengtao Gong, Jianhua Li, Xichen Zhang, Nan Zhang","doi":"10.1080/21691401.2024.2347377","DOIUrl":null,"url":null,"abstract":"Lung cancer is a dangerous disease that is lacking in an ideal therapy. Here, we evaluated the anti-lung cancer effect in nude mice of a fully human single-chain antibody (scFv) against the associated antigen 7 transmembrane receptor (Ts7TMR), which is also called G protein-coupled receptor, between A549 cells and Trichinella spiralis (T. spiralis). Our data showed that anti-Ts7TMR scFv could inhibit lung cancer growth in a dose-dependent manner, with a tumour inhibition rate of 59.1%. HE staining did not reveal any obvious tissue damage. Mechanistically, immunohistochemical staining revealed that the scFv down-regulated the expression of PCNA and VEGF in tumour tissues. Overall, this study found that anti-Ts7TMR scFv could inhibit A549 lung cancer growth by suppressing cell proliferation and angiogenesis, which may provide a new strategy for treating lung cancer.","PeriodicalId":8736,"journal":{"name":"Artificial Cells, Nanomedicine, and Biotechnology","volume":"52 1","pages":"300-308"},"PeriodicalIF":4.5000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Artificial Cells, Nanomedicine, and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1080/21691401.2024.2347377","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/16 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Lung cancer is a dangerous disease that is lacking in an ideal therapy. Here, we evaluated the anti-lung cancer effect in nude mice of a fully human single-chain antibody (scFv) against the associated antigen 7 transmembrane receptor (Ts7TMR), which is also called G protein-coupled receptor, between A549 cells and Trichinella spiralis (T. spiralis). Our data showed that anti-Ts7TMR scFv could inhibit lung cancer growth in a dose-dependent manner, with a tumour inhibition rate of 59.1%. HE staining did not reveal any obvious tissue damage. Mechanistically, immunohistochemical staining revealed that the scFv down-regulated the expression of PCNA and VEGF in tumour tissues. Overall, this study found that anti-Ts7TMR scFv could inhibit A549 lung cancer growth by suppressing cell proliferation and angiogenesis, which may provide a new strategy for treating lung cancer.

查看原文本刊更多论文

全人源单链抗体对 A549 细胞与螺旋体毛霉菌间相关抗原 Ts7TMR 的裸鼠肺癌抗肿瘤作用。

肺癌是一种缺乏理想疗法的危险疾病。在此，我们评估了全人源单链抗体（scFv）对A549细胞和螺旋体旋毛虫（T. spiralis）之间的相关抗原7跨膜受体（Ts7TMR）（也称G蛋白偶联受体）的裸鼠抗肺癌效果。我们的数据显示，抗Ts7TMR scFv能以剂量依赖的方式抑制肺癌的生长，肿瘤抑制率为59.1%。HE 染色未发现任何明显的组织损伤。免疫组化染色显示，scFv 下调了肿瘤组织中 PCNA 和 VEGF 的表达。总之，本研究发现抗 Ts7TMR scFv 可通过抑制细胞增殖和血管生成来抑制 A549 肺癌的生长，这可能为治疗肺癌提供了一种新策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Artificial Cells, Nanomedicine, and Biotechnology BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ENGINEERING, BIOMEDICAL

CiteScore

10.90

自引率

0.00%

发文量

审稿时长

20 weeks

期刊介绍： Artificial Cells, Nanomedicine and Biotechnology covers the frontiers of interdisciplinary research and application, combining artificial cells, nanotechnology, nanobiotechnology, biotechnology, molecular biology, bioencapsulation, novel carriers, stem cells and tissue engineering. Emphasis is on basic research, applied research, and clinical and industrial applications of the following topics:artificial cellsblood substitutes and oxygen therapeuticsnanotechnology, nanobiotecnology, nanomedicinetissue engineeringstem cellsbioencapsulationmicroencapsulation and nanoencapsulationmicroparticles and nanoparticlesliposomescell therapy and gene therapyenzyme therapydrug delivery systemsbiodegradable and biocompatible polymers for scaffolds and carriersbiosensorsimmobilized enzymes and their usesother biotechnological and nanobiotechnological approachesRapid progress in modern research cannot be carried out in isolation and is based on the combined use of the different novel approaches. The interdisciplinary research involving novel approaches, as discussed above, has revolutionized this field resulting in rapid developments. This journal serves to bring these different, modern and futuristic approaches together for the academic, clinical and industrial communities to allow for even greater developments of this highly interdisciplinary area.